Immune monitoring to characterize T-cell responses of kidney transplant patients during co-stimulation blockade by belatacept

Trial Profile

Immune monitoring to characterize T-cell responses of kidney transplant patients during co-stimulation blockade by belatacept

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 19 Nov 2013 Planned end date changed from 6 Sep 2014 to 1 May 2015 as reported by Netherlands Trial Register.
    • 19 Nov 2013 New source identified and integrated (Netherlands Trial Register; NTR4242).
    • 15 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top